RU2663127C2 - Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией - Google Patents

Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией Download PDF

Info

Publication number
RU2663127C2
RU2663127C2 RU2015139742A RU2015139742A RU2663127C2 RU 2663127 C2 RU2663127 C2 RU 2663127C2 RU 2015139742 A RU2015139742 A RU 2015139742A RU 2015139742 A RU2015139742 A RU 2015139742A RU 2663127 C2 RU2663127 C2 RU 2663127C2
Authority
RU
Russia
Prior art keywords
selenium
subject
yeast
composition
present application
Prior art date
Application number
RU2015139742A
Other languages
English (en)
Russian (ru)
Other versions
RU2015139742A (ru
Inventor
Ронан Пауэр
Кейси ЭГАН
Александр ЙАННИКУРИС
Цзы-Цзянь ЛАНЬ
Жицзинь СЯО
Льюис Коллен ДЖЕКСОН
Стефан Квятковски
Original Assignee
Олтек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олтек, Инк. filed Critical Олтек, Инк.
Publication of RU2015139742A publication Critical patent/RU2015139742A/ru
Application granted granted Critical
Publication of RU2663127C2 publication Critical patent/RU2663127C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015139742A 2013-03-15 2014-03-14 Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией RU2663127C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
US61/788,133 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
RU2015139742A RU2015139742A (ru) 2017-04-21
RU2663127C2 true RU2663127C2 (ru) 2018-08-01

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015139742A RU2663127C2 (ru) 2013-03-15 2014-03-14 Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией

Country Status (15)

Country Link
US (1) US9833486B2 (https=)
EP (1) EP2968404A4 (https=)
JP (1) JP6313418B2 (https=)
KR (1) KR102245702B1 (https=)
CN (3) CN114533753A (https=)
AU (1) AU2014228785B2 (https=)
BR (1) BR112015022514A2 (https=)
CA (1) CA2903845C (https=)
CL (1) CL2015002677A1 (https=)
HK (1) HK1216506A1 (https=)
MX (1) MX359626B (https=)
RU (1) RU2663127C2 (https=)
SG (2) SG10202101918RA (https=)
WO (1) WO2014144776A1 (https=)
ZA (1) ZA201506759B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384232B (es) 2013-03-14 2025-03-14 Jerome J Schentag Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
RU2665135C2 (ru) * 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
AU2018269403B2 (en) 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
JP7250810B2 (ja) * 2018-04-25 2023-04-03 オンコクロス カンパニー，リミテッド 筋肉疾患の予防及び治療用組成物
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
US20230129707A1 (en) * 2020-06-29 2023-04-27 Bristol-Myers Squibb Company Automated system and method for analyzing samples from a bioreactor
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
CN120531844A (zh) * 2025-07-02 2025-08-26 内蒙古肽元生物科技有限公司 生物活性肽在增强哺乳动物卵母细胞成熟及胚胎发育潜能中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
EP1774972B1 (en) * 2005-10-14 2012-02-29 Alltech, Inc. Use of selenium yeasts in the treatment of Alzheimers disease
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物
EA017496B1 (ru) * 2007-10-16 2012-12-28 Эксишоль С.А. Композиция для регулирования метаболизма липидов

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
US5221545A (en) 1992-03-09 1993-06-22 Abbott Laboratories Method of providing selenium in a nutritional product
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6911550B2 (en) 2003-02-21 2005-06-28 Zinpro Corporation Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
OA13177A (en) * 2003-06-04 2006-12-13 Willem Jacob Serfontein Nutritional compositions and use thereof.
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20050069594A1 (en) 2003-08-11 2005-03-31 Jan Lubinski Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
EP3095458B1 (en) * 2009-10-22 2018-07-25 Propanc Pty Ltd Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
US8575320B2 (en) 2010-03-18 2013-11-05 Alltech, Inc. Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins
WO2011132799A1 (en) * 2010-04-22 2011-10-27 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1774972B1 (en) * 2005-10-14 2012-02-29 Alltech, Inc. Use of selenium yeasts in the treatment of Alzheimers disease
EP1779858B1 (en) * 2005-10-14 2013-01-09 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
EA017496B1 (ru) * 2007-10-16 2012-12-28 Эксишоль С.А. Композиция для регулирования метаболизма липидов
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
IWIG D. "Investigation of the Catalytic Mechanism of the Reaction Catalyzed by Escherichia coli Cyclopropane Fatty Acid Synthase.", DISSERTATION, 2006, pages 1-267, см. c. 42, 44, 47, 51-54, 208, 217. *
MARSHALL J. R. et al. "Methyl Selenocysteine: Single-Dose Pharmacokinetics in Men", Cancer Prev Res., 2011, v. 4, p. 1938-1944. *
PINTO ET AL. "Supranutritional selenium induces alterations in molecular targets related to energy metabolism in skeletal muscle and visceral adipose tissue of pigs", J. INORG BIOCHEM., 2012, v. 114, p. 47-54. *
PINTO ET AL. "Supranutritional selenium induces alterations in molecular targets related to energy metabolism in skeletal muscle and visceral adipose tissue of pigs", J. INORG BIOCHEM., 2012, v. 114, p. 47-54. IWIG D. "Investigation of the Catalytic Mechanism of the Reaction Catalyzed by Escherichia coli Cyclopropane Fatty Acid Synthase.", DISSERTATION, 2006, pages 1-267, см. c. 42, 44, 47, 51-54, 208, 217. Найдено в Интернет [11.01.2018], URL: http://pdfsecret.com/download/investigation-of-the-catalytic-mechanism-of-the-reaction-catalyzed-by-_59f70365d64ab20a7511587e_pdf>. MARSHALL J. R. et al. "Methyl Selenocysteine: Single-Dose Pharmacokinetics in Men", Cancer Prev Res., 2011, v. 4, p. 1938-1944. *
SNYDER J. L.R. "Genomic Analysis of the Influence of Selenium Sources in Broiler Chickens Challenged with an Enteric Avian Reovirus", MASTERS THESIS, 2009, p. 1-243. *
Найдено в Интернет [11.01.2018], URL: http://pdfsecret.com/download/investigation-of-the-catalytic-mechanism-of-the-reaction-catalyzed-by-_59f70365d64ab20a7511587e_pdf>. *

Also Published As

Publication number Publication date
KR102245702B1 (ko) 2021-04-28
MX359626B (es) 2018-10-01
SG11201507061XA (en) 2015-10-29
US9833486B2 (en) 2017-12-05
US20160113977A1 (en) 2016-04-28
EP2968404A4 (en) 2017-01-04
JP6313418B2 (ja) 2018-04-18
JP2016516058A (ja) 2016-06-02
AU2014228785B2 (en) 2018-01-25
CA2903845A1 (en) 2014-09-18
KR20150132374A (ko) 2015-11-25
AU2014228785A1 (en) 2015-09-24
EP2968404A1 (en) 2016-01-20
RU2015139742A (ru) 2017-04-21
BR112015022514A2 (pt) 2017-07-18
CL2015002677A1 (es) 2016-12-09
MX2015013275A (es) 2015-12-11
CN114984038A (zh) 2022-09-02
CA2903845C (en) 2022-08-23
SG10202101918RA (en) 2021-03-30
NZ711842A (en) 2021-04-30
HK1216506A1 (zh) 2016-11-18
CN114533753A (zh) 2022-05-27
ZA201506759B (en) 2017-03-29
CN105377271A (zh) 2016-03-02
WO2014144776A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
RU2663127C2 (ru) Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией
Yuan et al. Exercise‐induced α‐ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1‐dependent adrenal activation
Mandaviya et al. Homocysteine and DNA methylation: a review of animal and human literature
JP6313479B2 (ja) 有機セレン化合物の組成物およびその使用方法
Liu et al. Blueberry anthocyanins-enriched extracts attenuate cyclophosphamide-induced cardiac injury
JP2022122921A (ja) ヒト老化から防御するためおよびそれによる劣化を修復するための生物学的経路のリセット
Nizon et al. Leukoencephalopathy with cysts and hyperglycinemia may result from NFU1 deficiency
JP2017214413A (ja) エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法
Wang et al. Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia
Pan et al. Ergothioneine exhibits longevity-extension effect in Drosophila melanogaster via regulation of cholinergic neurotransmission, tyrosine metabolism, and fatty acid oxidation
Zou et al. Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction
EP4279127A2 (en) Growth differentiation factor 15 as biomarker for metformin
Gu et al. β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice
US20220295855A1 (en) Methods and Compositions for Slowing an Aging Process in a Human or an Animal
Wu et al. Catalpol inhibits HHcy-induced EndMT in endothelial cells by modulating ROS/NF-κB signaling
Liu et al. A preliminary report on the toxicity of arecoline on early pregnancy in mice
CN111888359A (zh) 一种吡咯喹啉醌在抗哮喘及变态反应药物中的应用
Gu et al. Phlorizin mitigates high glucose-induced metabolic disorders through the IIS pathway in Caenorhabditis elegans
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
US20230000888A1 (en) Nad-precursors and dietary restriction for treating age related medical conditions
Yan et al. Liquiritigenin alleviates high-salt diet-induced heart damage by inhibiting TGF-β1/Smad signaling and reducing inflammation and fibrosis
Yang et al. Comprehensive analysis of yak milk residue peptides for anti-hypoxic functional foods: targeting neuroinflammation and apoptosis in hypoxic mice
Zhai et al. Quercetin’s antitumor effect in bladder cancer: Synergistic regulation of gut microbiota and L-serine metabolic pathway
Li et al. Artemisiae Scopariae Herba (Yinchen) suppresses ferroptosis in mice with osteoporosis via the Nrf2/Slc7a11/Gpx4 pathway
Ahn et al. Unacylated Ghrelin Counteracts Contractile and Mitochondrial Dysfunction in Cancer Cachexia